Trends of Exposure to Acrylamide as Measured by Urinary Biomarkers Levels within the HBM4EU Biomonitoring Aligned Studies (2000–2021)
Michael Poteser,
Federica Laguzzi,
Thomas Schettgen,
Nina Vogel,
Till Weber,
Aline Murawski,
Phillipp Schmidt,
Maria Rüther,
Marike Kolossa-Gehring,
Sónia Namorado,
An Van Nieuwenhuyse,
Brice Appenzeller,
Edda Dufthaksdóttir,
Kristín Olafsdóttir,
Line Småstuen Haug,
Cathrine Thomsen,
Fabio Barbone,
Valentina Rosolen,
Loïc Rambaud,
Margaux Riou,
Thomas Göen,
Stefanie Nübler,
Moritz Schäfer,
Karin H. A. Zarrabi,
Liese Gilles,
Laura Rodriguez Martin,
Greet Schoeters,
Ovnair Sepai,
Eva Govarts,
Hanns Moshammer
Affiliations
Michael Poteser
Department of Environmental Health, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria
Federica Laguzzi
Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska-Institutet, Nobels väg 13, Box 210, 17177 Stockholm, Sweden
Thomas Schettgen
Institute for Occupational, Social and Environmental Medicine, Medical Faculty, RWTH Aachen University, Pauwelsstrasse 30, 52074 Aachen, Germany
Nina Vogel
German Environment Agency (UBA), 14193 Berlin, Germany
Till Weber
German Environment Agency (UBA), 14193 Berlin, Germany
Aline Murawski
German Environment Agency (UBA), 14193 Berlin, Germany
Phillipp Schmidt
German Environment Agency (UBA), 14193 Berlin, Germany
Maria Rüther
German Environment Agency (UBA), 14193 Berlin, Germany
Marike Kolossa-Gehring
German Environment Agency (UBA), 14193 Berlin, Germany
Sónia Namorado
Department of Epidemiology, National Institute of Health Dr. Ricardo Jorge, 1649-016 Lisbon, Portugal
An Van Nieuwenhuyse
Laboratoire National de Santé (LNS), L-3555 Dudelange, Luxembourg
Brice Appenzeller
Department of Precision Health, Luxembourg Institute of Health (LIH), L-4354 Esch-sur-Alzette, Luxembourg
Edda Dufthaksdóttir
Faculty of Food Science and Nutrition, School of Health Sciences, University of Iceland, 102 Reykjavik, Iceland
Kristín Olafsdóttir
Department of Pharmacology and Toxicology, University of Iceland, 120 Reykjavik, Iceland
Line Småstuen Haug
Norwegian Institute of Public Health, Lovisenberggata 8, 0456 Oslo, Norway
Cathrine Thomsen
Norwegian Institute of Public Health, Lovisenberggata 8, 0456 Oslo, Norway
Fabio Barbone
Department of Medical Area, DAME, University of Udine, 33100 Udine, Italy
Valentina Rosolen
Institute for Maternal and Child Health-IRCCS “Burlo Garofolo”, 34137 Trieste, Italy
Loïc Rambaud
Santé Publique France, French Public Health Agency (ANSP), 94415 Saint-Maurice, France
Margaux Riou
Santé Publique France, French Public Health Agency (ANSP), 94415 Saint-Maurice, France
Thomas Göen
Institute and Outpatient Clinic of Occupational, Social and Environmental Medicine, Friedrich-Alexander Universität Erlangen-Nürnberg, Henkestraße 9-11, 91054 Erlangen, Germany
Stefanie Nübler
Institute and Outpatient Clinic of Occupational, Social and Environmental Medicine, Friedrich-Alexander Universität Erlangen-Nürnberg, Henkestraße 9-11, 91054 Erlangen, Germany
Moritz Schäfer
Institute and Outpatient Clinic of Occupational, Social and Environmental Medicine, Friedrich-Alexander Universität Erlangen-Nürnberg, Henkestraße 9-11, 91054 Erlangen, Germany
Karin H. A. Zarrabi
Institute and Outpatient Clinic of Occupational, Social and Environmental Medicine, Friedrich-Alexander Universität Erlangen-Nürnberg, Henkestraße 9-11, 91054 Erlangen, Germany
Liese Gilles
VITO Health, Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium
Laura Rodriguez Martin
VITO Health, Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium
Greet Schoeters
VITO Health, Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium
Ovnair Sepai
UK Health Security Agency, London SE1 8UG, UK
Eva Govarts
VITO Health, Flemish Institute for Technological Research (VITO), 2400 Mol, Belgium
Hanns Moshammer
Department of Environmental Health, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria
Acrylamide, a substance potentially carcinogenic in humans, represents a very prevalent contaminant in food and is also contained in tobacco smoke. Occupational exposure to higher concentrations of acrylamide was shown to induce neurotoxicity in humans. To minimize related risks for public health, it is vital to obtain data on the actual level of exposure in differently affected segments of the population. To achieve this aim, acrylamide has been added to the list of substances of concern to be investigated in the HBM4EU project, a European initiative to obtain biomonitoring data for a number of pollutants highly relevant for public health. This report summarizes the results obtained for acrylamide, with a focus on time-trends and recent exposure levels, obtained by HBM4EU as well as by associated studies in a total of seven European countries. Mean biomarker levels were compared by sampling year and time-trends were analyzed using linear regression models and an adequate statistical test. An increasing trend of acrylamide biomarker concentrations was found in children for the years 2014–2017, while in adults an overall increase in exposure was found to be not significant for the time period of observation (2000–2021). For smokers, represented by two studies and sampling for, over a total three years, no clear tendency was observed. In conclusion, samples from European countries indicate that average acrylamide exposure still exceeds suggested benchmark levels and may be of specific concern in children. More research is required to confirm trends of declining values observed in most recent years.